Literature DB >> 8911859

Expression of nitric oxide synthase in ulcerative colitis.

A J Godkin1, A J De Belder, L Villa, A Wong, J E Beesley, S P Kane, J F Martin.   

Abstract

Nitric oxide (NO) is generated from L-arginine by a family of enzymes called the NO synthases. Previous investigators have proposed that the expression of this inducible enzyme (iNOS) may account for the characteristic vasodilatation, oedema and impairment of get motility seen in active ulcerative colitis. Using a specific antibody to iNOS, we have investigated the distribution of this enzyme in colonic tissue from patients with histologically proven ulcerative colitis. Eight patients with ulcerative colitis expressed calcium-independent citrulline activity (9.96 +/- 2.34 pmol citrulline mg-1 protein min-1) and showed immunoreactivity to the iNOS antibody within the inflammatory infiltrate of the lamina propria, and also within the cytoplasm of the epithelial cells lining the colon. Five age-matched controls showed no calcium-independent citrulline activity (0.2 +/- 0.08 pmol citrulline mg-1 protein min-1) and no immunoreaction to the antibody. We conclude that this enzyme is present in colonic tissue including the epithelium from patients with active colitis. Inhibition of this enzyme may provide a novel therapeutic option for patients with active ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911859     DOI: 10.1111/j.1365-2362.1996.tb02131.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  26 in total

1.  Potentiation of cytokine induced iNOS expression in the human intestinal epithelial cell line, DLD-1, by cyclic AMP.

Authors:  M Cavicchi; B J Whittle
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Expression of inducible nitric oxide synthase in human gastric cancer.

Authors:  Yu Jun; Guo Fei; Matthias P A Ebert; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

Review 3.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

4.  A hexane fraction of American ginseng suppresses mouse colitis and associated colon cancer: anti-inflammatory and proapoptotic mechanisms.

Authors:  Deepak Poudyal; Phuong Mai Le; Tia Davis; Anne B Hofseth; Alena Chumanevich; Alexander A Chumanevich; Michael J Wargovich; Mitzi Nagarkatti; Prakash S Nagarkatti; Anthony Windust; Lorne J Hofseth
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-31

5.  Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders.

Authors:  Tryggve Ljung; Sofie Lundberg; Mark Varsanyi; Catharina Johansson; Peter T Schmidt; Max Herulf; Jon O Lundberg; Per M Hellstrom
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 6.  Inducible nitric oxide synthase in human diseases.

Authors:  K D Kröncke; K Fehsel; V Kolb-Bachofen
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

7.  The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon.

Authors:  P J Roberts; G P Riley; K Morgan; R Miller; J O Hunter; S J Middleton
Journal:  J Clin Pathol       Date:  2001-04       Impact factor: 3.411

Review 8.  Nitric oxide as a modulator of intestinal water and electrolyte transport.

Authors:  A A Izzo; N Mascolo; F Capasso
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

Review 9.  iNOS expression in oral and gastrointestinal tract mucosa.

Authors:  Nurullah Keklikoglu; Meltem Koray; Humeyra Kocaelli; Sevtap Akinci
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

10.  Crocetin reduces TNBS-induced experimental colitis in mice by downregulation of NFkB.

Authors:  Hamid A Kazi; Zhiyu Qian
Journal:  Saudi J Gastroenterol       Date:  2009 Jul-Sep       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.